NetraMark

NetraMark's NetraAI analyzes clinical trial data to uncover which patient subgroups respond to a treatment, which variables drive the response and what causes placebo effects or adverse events. Drug developers use it to design tighter protocols and rescue struggling trials.

NetraAI is built on Attractor AI, a proprietary long-range attractor algorithm meant to find hidden relationships between patients and explain them clearly. The insights feed inclusion and exclusion criteria, dose selection and enrichment strategies, aiming for larger effect sizes and smaller phase III studies.

NetraMark is a public company listed in Toronto, Frankfurt and on the OTCQB, and it publishes posters, white papers and peer-reviewed studies on its methods. Work is arranged directly with sponsors, so there is no self-serve pricing.